EXELIXIS, INC. (EXEL)

50.15 0.53 (1.07%)

As of 2026-05-22 14:59:45 EST

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Traded asNasdaq: EXEL
ISINUS30161Q1040
CIK0000939767
LEI254900PJQB59O2O95R37
EIN043257395
SectorBiotechnology
IndustryBiological Products, (No Diagnostic Substances)
CEOMichael M. Morrissey, Ph.D.
Employees954
Fiscal Year End0101
Address1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
Phone6508377000
Websitehttp://exelixis.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
EXELEXELIXIS, INC.2026-05-22 14:59:4550.150.531.07
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
EXEL0000939767EXELIXIS, INC.US30161Q1040254900PJQB59O2O95R37043257395Nasdaq2836Biological Products, (No Diagnostic Substances)0101DE1851 HARBOR BAY PARKWAYALAMEDACA94502UNITED STATESUS65083770001851 HARBOR BAY PARKWAY, ALAMEDA, CA, 945021851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502EXELIXIS INCBiotechnology1994Michael M. Morrissey, Ph.D.954http://exelixis.com9,400,000,000253,701,000251,355,083Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.2026-05-21 15:53:08
This is a preview of the latest data. Subscribe to access the full data.
EXEL Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
EXEL Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20259,400,000,0004,600,000,00095.8333259,708,689-20,172,761-7.2076
20244,800,000,000100,000,0002.1277279,881,450-23,312,809-7.6891
20234,700,000,000-2,131,299,691-31.199303,194,259-20,893,078-6.4467
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Dana T. Aftab, Ph.D.Executive Vice President2025659,05809,479,940397,25011,00010,547,248
Brenda J. Hefti, J.D.General Counsel, Senior Vice President2025454,54503,451,975286,75111,0004,204,271
Christopher J. SennerChief Financial Officer, Executive Vice President2025822,82309,343,867470,78211,00010,648,472
Michael M. MorrisseyChief Executive Officer, President20251,306,040030,539,5521,382,59111,00033,239,183
Jeffrey J. Hessekiel, J.D.General Counsel, Executive Vice President2025672,37408,309,218011,0008,992,592
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20261,077
20251,147
20231,310
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue2,320,126,0002,168,701,0001,830,208,000
Cost Of Revenue83,697,00076,216,00072,547,000
Gross Profit2,236,429,0002,092,485,0001,757,661,000
Research And Development Expenses825,001,000910,408,0001,044,071,000
General And Administrative Expenses518,727,000492,128,000542,705,000
Operating Expenses1,447,935,0001,564,084,0001,659,323,000
Operating Income872,191,000604,617,000170,885,000
Net Income782,570,000521,267,000207,765,000
Earnings Per Share Basic2.881.80.65
Earnings Per Share Diluted2.781.760.65
Weighted Average Shares Outstanding Basic271,567,000290,030,000318,151,000
Weighted Average Shares Outstanding Diluted281,863,000296,132,000321,464,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents482,488,000217,374,000262,994,000
Marketable Securities Current576,603,000893,902,000732,308,000
Accounts Receivable286,916,000265,437,000237,407,000
Inventories21,686,00022,388,00017,323,000
Non Trade Receivables———
Other Assets Current75,596,00068,478,00067,926,000
Total Assets Current1,443,289,0001,467,579,0001,317,958,000
Marketable Securities Non Current603,603,000637,291,000728,717,000
Property Plant And Equipment98,960,000119,391,000128,731,000
Other Assets Non Current———
Total Assets Non Current1,401,134,0001,480,111,0001,624,399,000
Total Assets2,844,423,0002,947,690,0002,942,357,000
Accounts Payable29,623,00038,191,00033,768,000
Deferred Revenue1,115,0002,739,0005,406,000
Short Term Debt———
Other Liabilities Current125,382,00095,012,000108,417,000
Total Liabilities Current405,644,000403,769,000394,277,000
Long Term Debt———
Other Liabilities Non Current104,422,000108,895,00094,224,000
Total Liabilities Non Current277,460,000299,718,000284,168,000
Total Liabilities683,104,000703,487,000678,445,000
Common Stock262,000282,000303,000
Retained Earnings-76,830,000-98,647,000-173,351,000
Accumulated Other Comprehensive Income3,476,000-1,347,000-3,750,000
Total Shareholders Equity2,161,319,0002,244,203,0002,263,912,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization29,055,00028,803,00025,717,000
Share Based Compensation Expense112,983,00093,836,000106,345,000
Other Non Cash Income Expense11,609,00013,626,00016,797,000
Change In Accounts Receivable21,398,00027,950,00022,623,000
Change In Inventories-12,225,000-5,453,00012,977,000
Change In Non Trade Receivables———
Change In Other Assets133,771,000-31,079,00029,824,000
Change In Accounts Payable-50,152,000-21,886,00053,246,000
Change In Other Liabilities1,899,000-149,0001,345,000
Cash From Operating Activities884,267,000699,971,000333,324,000
Purchases Of Marketable Securities632,497,000927,905,000902,468,000
Sales Of Marketable Securities1,022,866,000877,307,0001,038,482,000
Acquisition Of Property Plant And Equipment8,429,00028,435,00040,469,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities350,441,000-116,783,000-26,955,000
Tax Withholding For Share Based Compensation71,220,00038,625,00029,122,000
Payments Of Dividends———
Issuance Of Common Stock49,154,00061,780,00033,494,000
Repurchase Of Common Stock1,159,700,000661,229,000554,870,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities-969,594,000-628,808,000-546,052,000
Change In Cash265,114,000-45,620,000-239,683,000
Cash At End Of Period482,488,000217,374,000262,994,000
Income Taxes Paid155,296,000170,482,000185,658,000
Interest Paid———
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share2.881.80.65
Price To Earnings Ratio15.131918.872236.9077
Earnings Growth Rate60176.923114.0351
Price Earnings To Growth Ratio0.25220.10672.6297
Book Value Per Share7.95877.73787.1158
Price To Book Ratio5.47584.39013.3714
Ebitda966,921,000720,552,000419,140,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures8,624,00019,463,00043,824,000
Free Cash Flow875,643,000680,508,000289,500,000
Return On Equity0.36210.23230.0918
One Year Beta0.5680.20020.3988
Three Year Beta0.44130.5860.6831
Five Year Beta0.60510.7240.8069
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Haley Patrick J.EVP, Commercial2026-05-2032,110D357,638
Hefti BrendaSVP and General Counsel2026-05-186,625D106,762
Senner Christopher J.EVP and CFO2026-05-1834,901D952,317
MORRISSEY MICHAELDirector, President and CEO2026-05-18124,047D1,362,008
MORRISSEY MICHAELDirector, President and CEO2026-05-18124,047A2,004,327
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
WINNOW WEALTH LLC2026-03-31844,92119,70042.8894
Western Wealth Management, LLC2026-03-3128,86567342.89
McIlrath & Eck, LLC2026-03-3119,47245442.8899
FWL INVESTMENT MANAGEMENT, LLC2026-03-313,9469242.8913
Focus Partners Wealth2026-03-314,622,538107,77642.8902
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
iSHARES TRUST2026-03-31iShares Russell 1000 Value ETFIWD119,2985,116,691.220.0073
iSHARES TRUST2026-03-31iShares Russell 1000 Growth ETFIWF859,48436,863,268.760.033
iSHARES TRUST2026-03-31iShares Russell 1000 ETFIWB191,5508,215,579.50.0192
AQR Funds2026-03-31Class R6QLERX899,82338,593,408.470.4781
AQR Funds2026-03-31Class NQLENX899,82338,593,408.470.4781
This is a preview of the latest data. Subscribe to access the full data.